Health TrialsbyHealthPanel

Precision Cancer Therapy in Rare Cancers

ConditionRare Malignant Neoplasm
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age16-99
SponsorOslo University Hospital

About this trial

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

ECOG 0-2,

identified biomarker,

reasonable biochemistry

Disqualifiers

ECOG 3-5

serious other diseases

Trial design

Design model

Single group

Treatments tested in this trial

  • Imatinib

    Drug

    imatinib treatment based on molecular alterations

  • Trametinib

    Drug

    According to biomarkers

  • Dabrafenib

    Drug

    According to biomarkers

Treatment groups

96 Participants
are divided into 1 treatment group
Group A: treatment according to genetic alterationsExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Radiological response evaluation at 16 weeks of treatment

Standard radiological response evaluation, like RECIST criteria.

Time frame
16 weeks

Secondary outcomes

1

Molecular analyses predicting responses

Sequencing of tumor material and blood samples

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Oslo University Hospital

Lead sponsor

Helse Stavanger HF

Collaborator

University Hospital of North Norway

Collaborator

StOlavs Hospital

Collaborator

Nordlandssykehuset HF

Collaborator

Helse Nord-Trøndelag HF

Collaborator

Sorlandet Hospital HF

Collaborator

Møre og Romsdal Hospital Trust

Collaborator

The Hospital of Vestfold

Collaborator

Helse Fonna

Collaborator

Haukeland University Hospital

Collaborator

Sykehuset Ostfold

Collaborator

Helse Forde

Collaborator

Sykehuset Innlandet HF

Collaborator

Source ClinicalTrials.gov
Apply now